Financial giants have made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer PFE revealed 33 unusual trades.
Delving into the details, we found 39% of traders were bullish, while 60% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $974,402, and 27 were calls, valued at $1,051,170.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $37.5 for Pfizer, spanning the last three months.
Insights into Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale trades within a strike price range from $20.0 to $37.5 in the last 30 days.
Pfizer Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| PFE | PUT | TRADE | NEUTRAL | 01/17/25 | $27.50 | $752.9K | 20.3K | 10.1K |
| PFE | CALL | SWEEP | BULLISH | 12/19/25 | $20.00 | $172.4K | 1.4K | 0 |
| PFE | CALL | SWEEP | BULLISH | 01/16/26 | $30.00 | $86.0K | 12.8K | 654 |
| PFE | PUT | SWEEP | BEARISH | 01/17/25 | $30.00 | $67.0K | 18.1K | 250 |
| PFE | PUT | SWEEP | BEARISH | 02/16/24 | $28.00 | $49.9K | 8.2K | 130 |
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance.
Current Position of Pfizer
- With a trading volume of 31,040,662, the price of PFE is up by 0.44%, reaching $29.86.
- Current RSI values indicate that the stock is may be approaching overbought.
- Next earnings report is scheduled for 27 days from now.
Professional Analyst Ratings for Pfizer
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $30.333333333333332.
- An analyst from Barclays has decided to maintain their Equal-Weight rating on Pfizer, which currently sits at a price target of $28.
- An analyst from Truist Securities persists with their Buy rating on Pfizer, maintaining a target price of $36.
- Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Pfizer with a target price of $27.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Pfizer, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
